SEATTLE — The investigational integrase inhibitor bictegravir worked as well as dolutegravir (Tivicay) and caused no serious side effects when used as part of a three-drug antiretroviral therapy regimen, a researcher said here. Bictegravir is now being evaluated in phase III studies. Viral suppression rates were high in both treatment arms and no one taking...